Anti-aging company Unity closes $151M series B

Unity Biotechnology Inc. (San Francisco, Calif.) raised $35 million in the second close of a series B round, bringing the total amount raised in the round to $151 million. New investors in the round included Invus Opportunities, Three Lakes Partners, Cycad Group, COM Investments and Pivotal Alpha, while existing investors Arch Venture Partners, Baillie Gifford, Fidelity Management & Research Company, Partner Fund Management and Venrock also participated. Other investors included Bezos Expeditions, Vulcan Capital, Founders Fund, the WuXi PharmaTech Inc. subsidiary of New WuXi Life Science Ltd. (Shanghai, China) and Mayo Clinic Ventures.

According to BioCentury's BCIQ database, the financing is the 8th largest series B round since BioCentury started tracking financings in 1994...